1. Robotic surgery still moving forward
Robotic surgical systems are taking a tighter hold, even as the pandemic applies pressures. Stryker (NYSE:SYK), for example, has had a great deal of success in the robotic orthopedic surgery space with its Mako robots. CEO Kevin Lobo is optimistic about the post-pandemic future:
“There’s a momentum, there’s a belief that this is the future. And so we’re past the early adopter phase now, we have hospitals buying their second, third, fourth, fifth, Mako large systems and we have competitive pressures of course that occur related to that, but the evidence and that the happy patients that are telling their stories and surgeons seeing great results, I think we still have a long way to go. It’s still very early in the cycle, and we’re pretty excited about the degree of interest even through a pandemic to be able to have that type of interest means, we really are getting to the point where it’s starting to become accepted.”